Silence Therapeutics plc (SLN) Earnings
Silence Therapeutics plc is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.14. SLN has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise -21.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.33 | $-0.32 | +3.0% | $422000 | -66.4% |
| Mar 5, 2026 | $-0.32 | $-0.25 | +21.9% | $34000 | -98.5% |
| Nov 6, 2025 | $-0.40 | $-0.45 | -12.5% | $159000 | -94.9% |
| Aug 7, 2025 | $-0.27 | $-0.54 | -100.0% | $224000 | -93.1% |
| May 8, 2025 | $-0.18 | $-0.60 | -233.3% | $183707 | -92.1% |
| Nov 14, 2024 | $-0.42 | $-0.75 | -78.6% | $1M | -73.7% |
| May 16, 2024 | $-0.23 | $-0.05 | +78.3% | $16M | +146.4% |
| Nov 14, 2023 | $-0.56 | $-0.28 | +50.0% | $3M | +16.7% |
| Aug 16, 2023 | $-0.59 | $-0.36 | +39.0% | $12M | +202.5% |
| May 16, 2023 | $-0.51 | $-0.35 | +31.4% | $14M | +347.4% |
| Nov 10, 2022 | $-0.60 | $-0.25 | +58.3% | $4M | — |
| Aug 11, 2022 | $-0.60 | $-0.16 | +73.1% | $4M | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2024 · February 28, 2025
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Zerlasiran: ALPACAR-360 Phase 2 study showed Lp(a) reductions >90%, well tolerated. Phase 3 program design highly differentiated, met with positive regulatory feedback. Phase 3 outcomes study will be initiated only once a partner is secured. - Divesiran: SANRECO Phase 1 study showed complete elimination of phlebotomy need in well-controlled patients, safety/tolerability favorable. Started SANRECO Phase 2 study, EU granted Orphan Drug Designation for PV, FDA Fast Track and Orphan Drug Designations also obtained. - Pipeline advancements: Third siRNA from GOLD platform entered clinic under AstraZeneca collaboration. Progressed preclinical siRNA candidates for hepatic targets. Plan to start Phase 1 study of SLN548 in second half of 2025. - 2025 priorities: Prioritizing investment in programs targeting rare conditions with first-in-class/best-in-class siRNAs. Focus on divesiran for PV, and advancing other pipeline programs including extrahepatic work.
Guidance
- Will only initiate zerlasiran Phase 3 outcomes study once a partner is secured, extending cash runway into 2027. - Prioritizing programs targeting rare conditions with clear unmet needs for innovative siRNA therapies, including divesiran for PV. - Anticipate full enrollment in SANRECO Phase 2 study by end of 2024. Plan to start Phase 1 study of SLN548 in second half of 2025.
Segment performance
For the year ended December 31, 2024, Silence recorded $43.3 million in revenues versus $31.6 million in 2023. The increase was largely due to collaboration arrangements. Revenue from the AstraZeneca collaboration advanced nicely, and from the Hansoh Pharma collaboration, $24.6 million was recognized in 2024 due to cumulative catch-up. Expenses: R&D costs were $67.9 million in 2024 vs $56.9 million in 2023, primarily due to advancing zerlasiran and divesiran programs. General and administrative costs were $26.9 million in 2024 vs $26.2 million in 2023, driven by transition to U.S. domestic issuer requirements. Net operating loss in 2024 was approximately $63.3 million vs $64.4 million in 2023, with net loss at $45.3 million vs $54.2 million in 2023. Cash, cash equivalents, and short-term investments were $147.3 million at year-end 2024.
Risks & headwinds
Actual results may differ materially from forward-looking statements due to various factors including those in the most recent annual report on file with the SEC and future filings. No specific operational failures discussed in detail.
Analyst Q&A
Q: Provide color on partnership discussions for zerlasiran and importance of HORIZON data, types of partnership structures considered?
A: Not to comment specifically on ongoing discussions, but actively engaged in partnering, confident in zerlasiran's potential, balance resources among products.
Q: How ready are you for Phase 3 trial of zerlasiran, timeline from securing partner, partner influence on Phase 3 design, evaluation of divesiran in hereditary hemochromatosis?
A: Phase 3 readiness activities on track to complete by mid-year. Can make fine-tuning with partner. Considering divesiran in hereditary hemochromatosis as it relates to the target.
Q: Goal for divesiran differentiation, differentiation vs rusfertide besides dosing frequency, biggest hurdles in partnering zerlasiran?
A: Goal is to be first siRNA to market for PV, differentiation includes dosing frequency and symptomatic improvement. No single hurdle for partnering, dialogues around business strategy and market opportunity.
Q: Status of candidates developed for Hansoh, worth pursuing on own?
A: Interested in programs, have encouraging preclinical data, can develop ourselves or partner/license. Revenue from Hansoh is from cumulative catch-up, no further obligations.
Q: Regulatory discussions on zerlasiran dose, difference between endogenous trigger with TMPRSS6 inhibition and hepcidin mimetic in PV safety?
A: Not sharing specific dose info with regulators yet. Our approach of increasing hepcidin within physiological range is safe, correlation with clinical benefit seen in Phase 1, safety profile favorable